Effect of Medical Therapies for Endometriosis on Bone Health
Authors:
- 19 March 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 148 (2) , 205-215
Abstract
OBJECTIVE: To evaluate the effect of endometriosis medical therapies on bone mineral density (BMD). DATA SOURCES: Electronic databases were searched from inception to July 2025 for clinical studies reporting the effect of hormonal treatments for endometriosis on BMD. METHODS OF STUDY SELECTION: Eligible studies included randomized controlled trials (RCTs) and prospective and retrospective cohort studies involving women of reproductive age. Interventions assessed were gonadotropin-releasing hormone (GnRH) agonists with add-back therapy, dienogest, GnRH antagonists, and depot medroxyprogesterone acetate (DMPA). Risk of bias was evaluated with the Cochrane Risk of Bias Tool to evaluate RCTs, the Risk of Bias in Non-Randomized Studies of Interventions tool for nonrandomized trials, and the Newcastle–Ottawa Scale for cohort studies. A total of 1,153 studies were screened, of which 37 met inclusion criteria. TABULATION, INTEGRATION, AND RESULTS: Pooled analysis of GnRH agonist showed a decrease in BMD at 6 months (−0.89%, 95% CI, −1.45 to −0.33, I 2 =20.3%, 11 studies) and at 12 months (−1.50%, 95% CI, −2.68 to −0.31, I 2 =40.5%, four studies). Subgroup analysis by GnRH agonist type decreased heterogeneity and showed that at 6 months both leuprolide (−1.33%, 95% CI, −1.92 to −0.74, I 2 =0%, six studies) and goserelin (−0.42%, 95% CI, −1.00 to 0.16, I 2 =11%, five studies) with add-back decreased BMD. Dienogest was associated with lower BMD at 6 months (−0.83%, 95% CI, −1.52 to −0.15, I 2 =76.8%, six studies) and 12 months (−1.91%, 95% CI, −2.58 to −1.24. I 2 =83.7%, four studies); however, there were high heterogeneity and inconsistency between studies. GnRH antagonist decreased BMD at 6 months (−2.17%, 95% CI, −3.44 to −0.90, I 2 =97.3%, five studies), although most studies lacked add-back therapy. Data from four studies on DMPA could not be meta-analyzed. Risk of bias was low in studies included in the analysis. CONCLUSION: Hormonal suppression for endometriosis treatment is associated with a decrease in BMD after 12 months of use, with each medical therapy having a unique effect. The clinical significance of these findings remains uncertain, highlighting the need for expert consensus for bone health management in patients on long-term hormonal therapy. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42024580675.Keywords
This publication has 58 references indexed in Scilit:
- EndometriosisJAMA, 2025
- Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trialAmerican Journal of Obstetrics and Gynecology, 2024
- The Efficacy of Dienogest in Reducing Disease and Pain Recurrence After Endometriosis Surgery: a Systematic Review and Meta-AnalysisReproductive Sciences, 2023
- Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysisArchives of Gynecology and Obstetrics, 2023
- The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosisBone, 2022
- The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of EndometriomaReproductive Sciences, 2021
- Gonadotropin-releasing hormone agonist with add–back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosisArchives of Gynecology and Obstetrics, 2016
- Evaluation and Management of the Premenopausal Woman with Low BMDCurrent Osteoporosis Reports, 2013
- Bone density recovery after depot medroxyprogesterone acetate injectable contraception useContraception, 2008
- Progestogen-only contraception and bone mineral density: a systematic reviewContraception, 2006